Because of the easily observable, predictable, and progressive clinical paralytic phenotypes, this transgenic mouse model may be useful in preclinical trials of therapeutics targeting neurological disorders associated with elevated levels of TDP-43. This evidence concerns the gene TARDBP and nervous system disorder.